Table 5 The sensitivity analysis I: association between ranitidine and cancer risk by varying lag-time in propensity score matched cohort.
From: Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea
Lag-time | No. of events | 1000 person years | Incidence rate per 1000 person years (95% CI) | Crude HR | Adjusted HR† |
|---|---|---|---|---|---|
No lag-time applied | |||||
Ranitidine | 415 | 70.0 | 5.9 (5.4–6.5) | 1.09 (0.95–1.25) | 1.08 (0.94–1.24) |
Other H2RAs | 392 | 72.9 | 5.4 (4.9–5.9) | Reference | Reference |
Two years | |||||
Ranitidine | 205 | 70.0 | 2.9 (2.5–3.4) | 1.00 (0.83–1.21) | 0.98 (0.81–1.20) |
Other H2RAs | 216 | 72.9 | 3.0 (2.6–3.4) | Reference | Reference |
Four years | |||||
Ranitidine | 112 | 70.0 | 1.6 (1.3–1.9) | 1.03 (0.79–1.33) | 1.02 (0.79–1.33) |
Other H2RAs | 117 | 72.9 | 1.6 (1.3–1.9) | Reference | Reference |
Six years | |||||
Ranitidine | 63 | 70.0 | 0.9 (0.7–1.2) | 1.12 (0.79–1.59) | 1.12 (0.79–1.59) |
Other H2RAs | 61 | 72.9 | 0.8 (0.6–1.1) | Reference | Reference |
